EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Rethinking Drug Resistance in Acute Promyelocytic Leukemia: The Regulated Cell Death Network as an Integrative Framework

Shiyu Lin iD, Biaohan Qin, Zhexi Ye, Jiaqi Qing, Hui Zhen, Sennan Yang, Xin Jiang, Yiwen Fan, Lemei Zhu, Juan Liu

Biomolecules · 2026

DOI: 10.3390/biom16091375 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2026. Verfasst von Shiyu Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha 410219, China. Hauptthemen laut MEDLINE: Leukemia, Promyelocytic, Acute, Drug Resistance, Neoplasm. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Education Department of Hunan Province, the National College Students' Innovative Entrepreneurial Training Plan Program, the Innovation and Entrepreneurship Education Base of Public Health and Preventive Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug resistance in acute promyelocytic leukemia (APL) remains clinically challenging despite the success of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) therapy. Existing explanations, including promyelocytic leukemia protein–retinoic acid receptor alpha (PML–RARα) mutations and alterations in individual death pathways, do not fully account for the heterogeneity of resistant phenotypes. This review proposes regulated cell death network (RCDN) remodeling as a testable framework for APL resistance. RCDN remodeling is defined as coordinated changes in network coupling, stress routing, and cellular death thresholds. We hypothesize that resistance emerges from coordinated adaptation across redox, survival signaling, and mitochondrial gating, rather than from defects in any single pathway. This predicts coupled shifts across multiple death modules and non-additive responses to combinatorial perturbations, distinguishing network-level remodeling from pathway-specific resistance. We further define experimental criteria for distinguishing network-level remodeling from pathway-specific resistance and discuss Tanshinone IIA (Tan IIA) as a preclinical multi-node perturbation probe.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Promyelocytic, AcuteDrug Resistance, NeoplasmHumansTretinoinArsenic TrioxideCell DeathSignal TransductionAntineoplastic AgentsAnimals

Stichwörter der Autor:innen

APLATRA/ATO resistanceRCDNTan IIAmitochondrial primingnetwork remodelingredox signaling

Substanzen

TretinoinArsenic TrioxideAntineoplastic Agents

Autor:innen und Institutionen

  • Hunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha 410219, China.
  • Hunan Provincial University Key Laboratory of the Fundamental and Clinical Research on Neurodegenerative Diseases, Changsha Medical University, Changsha 410219, China.
  • School of Traditional Chinese Medicine, Changsha Medical University, Changsha 410219, China.
  • School of First Clinical, Changsha Medical University, Changsha 410219, China.
  • School of Public Health, Changsha Medical University, Changsha 410219, China.
  • School of Dental Medicine, Changsha Medical University, Changsha 410219, China.

ORCID-Profile: Shiyu Lin

Förderung

  • Education Department of Hunan Province
  • the National College Students' Innovative Entrepreneurial Training Plan Program
  • the Innovation and Entrepreneurship Education Base of Public Health and Preventive Medicine
  • Hunan Provincial Education Commission Foundation
  • National College Students’ Innovative Entrepreneurial Training Plan Program
  • Innovation and Entrepreneurship Education Base of Public Health and Preventive Medicine
  • Aid Program for Science and Technology Innovative Research Team in Higher Educational Institutions of Hunan Province, China

Zitieren

APA

Lin, S., Qin, B., Ye, Z., Qing, J., Zhen, H., Yang, S., Jiang, X., Fan, Y., Zhu, L., & Liu, J. (2026). Rethinking Drug Resistance in Acute Promyelocytic Leukemia: The Regulated Cell Death Network as an Integrative Framework. Biomolecules. https://doi.org/10.3390/biom16091375

Vancouver

Lin S, Qin B, Ye Z, Qing J, Zhen H, Yang S, et al. Rethinking Drug Resistance in Acute Promyelocytic Leukemia: The Regulated Cell Death Network as an Integrative Framework. Biomolecules. 2026. doi:10.3390/biom16091375

BibTeX
@article{Lin2026,
  author = {Lin, Shiyu and Qin, Biaohan and Ye, Zhexi and Qing, Jiaqi and Zhen, Hui and Yang, Sennan and Jiang, Xin and Fan, Yiwen and Zhu, Lemei and Liu, Juan},
  title = {Rethinking Drug Resistance in Acute Promyelocytic Leukemia: The Regulated Cell Death Network as an Integrative Framework},
  journal = {Biomolecules},
  year = {2026},
  doi = {10.3390/biom16091375}
}
Kostenlos starten →